Bengaluru, Mar 02: MedGenome, India’s leading genomics-driven diagnostics and research services company, today announced a majority investment in Mumbai-headquartered Medcare Management Services Pvt. Ltd., a leading radiology and nuclear medicine provider specializing in PET-CT and advanced molecular imaging services.
Founded in 2012 by Dr. Atul Marwah, a nuclear medicine expert with several decades of experience in establishing and leading nuclear medicine departments at Mumbai’s top hospitals, and Dr. Ruchira Marwah, a highly seasoned radiologist, Medcare has four fully integrated imaging facilities at Chembur, Goregaon, Andheri and Navi Mumbai. The company offers advanced imaging services, including PET-CT, CT, Mammography, Nuclear Medicine Scans, and theragnostic facilities. Over the past decade, through partnerships with over 50 hospitals and leading physicians across the city, Medcare has built credibility for its clinical excellence, accessibility, and patient care in the region.
Commenting on this alliance, Dr. Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, and Chairman of the Board of MedGenome, said,
“MedGenome’s investment in Medcare marks an important step in strengthening its vision of building an integrated diagnostics ecosystem for India. By bringing together Medcare’s imaging and pathology expertise with MedGenome’s leadership in multi‑omics, this partnership expands access to earlier and more precise diagnostics for patients. As an investor, Novo Holdings is pleased to support this next phase of growth as the company continues advancing high‑quality, science‑led healthcare.”
Surajit Chakrabartty, CFO of MedGenome, said,
“Integrating Medcare with MedGenome further strengthens our presence in western India and aligns with our long-term vision of building a unified, integrated diagnostics ecosystem. Diagnostics is the critical starting point in disease management. As leaders in omics-led diagnostics, this strengthens our ability to deliver comprehensive, end-to-end solutions across the patient journey. Our mission has been to improve early and accurate diagnosis and targeted treatment, making affordable precision healthcare accessible to patients across the country, and we will continue to work towards this with like-minded partners.”
Nuclear medicine plays a major role in the areas of Oncology, Cardiology, and Neurology for diagnosis as well as in treatment planning. PET-CT Imaging, complemented with genetic tests, enables early cancer detection and has a significant impact on the course of treatment and monitoring, delivering enhanced patient outcomes.
Dr. Atul Marwah, Founder, Medcare, added,
“For over a decade, Medcare has been committed to delivering high-quality, accessible radiology and nuclear medicine services to patients across Mumbai. As a part of MedGenome, Medcare can unlock significant growth opportunities, enabling us to offer integrated imaging, pathology, and genomics solutions, which are especially critical in oncology and the management of complex diseases. We’re excited to continue leading Medcare into its next phase of expansion.”
The collaboration fortifies MedGenome’s strategy of evolving into a truly integrated diagnostics player, with a focus on multi-omics. By strengthening its capabilities across radiology, pathology, and genomics, the company is poised to deliver more comprehensive, technology-driven, and patient-centric solutions, expand its reach and footprint, and improve the accessibility of advanced precision diagnostics across India.